Maximum 24-hour platelet count fall: Metric for improving the diagnosis of heparin-induced thrombocytopenia among patients with intermediate probability 4Ts scores.
anticoagulants/adverse effects
heparin/adverse effects
platelets
thrombocytopenia
thrombosis
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
08
02
2020
revised:
20
04
2020
accepted:
06
05
2020
pubmed:
21
5
2020
medline:
15
5
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Most patients with suspected heparin-induced thrombocytopenia (HIT) and an intermediate probability 4Ts score do not have HIT. We aimed to develop a metric based on the rate of platelet count fall to aid in discriminating HIT status among patients with an intermediate 4Ts score. We derived a measure of the maximum 24-hour percentage decrease in platelet count (Fall One hundred fifty-eight and 139 patients were included in the analysis from the derivation and validation cohorts, respectively. Fall Among patients with suspected HIT and an intermediate 4Ts score, Fall
Sections du résumé
BACKGROUND
Most patients with suspected heparin-induced thrombocytopenia (HIT) and an intermediate probability 4Ts score do not have HIT. We aimed to develop a metric based on the rate of platelet count fall to aid in discriminating HIT status among patients with an intermediate 4Ts score.
METHODS
We derived a measure of the maximum 24-hour percentage decrease in platelet count (Fall
RESULTS
One hundred fifty-eight and 139 patients were included in the analysis from the derivation and validation cohorts, respectively. Fall
CONCLUSIONS
Among patients with suspected HIT and an intermediate 4Ts score, Fall
Identifiants
pubmed: 32430965
doi: 10.1111/jth.14897
pii: S1538-7836(22)01620-8
doi:
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2018-2024Informations de copyright
© 2020 International Society on Thrombosis and Haemostasis.
Références
GreinacherA, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-851.
WarkentinTE. How I diagnose and manage HIT. Hematol Am Soc Hematol Educ Program. 2011;2011:143-149.
LoGK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
CukerA, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167.
CukerA, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392.
LubenowN, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and. J Thromb Haemost. 2005;3(11):2428-2436.
LewisBE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838-1843.
KangM, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6):924-929.
LoGK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007;82(12):1037-1043.
AsterRH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911-918.
McMahonCM, Cuker A. Hospital-acquired thrombocytopenia. Hosp Pract. 2014;42(4):142-152.
McCraeKR, Herman JH. Posttransfusion purpura: two unusual cases and a literature review. Am J Hematol. 1996;52(3):205-211.
PishkoAM, Fardin S, Lefler DS, et al. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3155-3162.
CinesDB, Kaywin P, Bina M, Tomaski A, Schreiber AD. Heparin-associated thrombocytopenia. N Engl J Med. 1980;303(14):788-795.
LinkinsL-A, Bates SM, Lee AYY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126(5):597-603.
SheridanD, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30.
ZarychanskiR, Houston DS. Assessing thrombocytopenia in the intensive care unit: the past, present, and future. Hematol Am Soc Hematol Educ Program. 2017;2017(1):660-666.
SullivanJ, Bak E, Sullivan MJ, Gurnani PK. Predictive value of scoring tools in determining heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation. Perfusion. 2019;24:267659119881266.